Oct 28HHS draft policy lets licensed pharmacies compound six peptides, including BPC-157. What changed and what did not.
Skip to content
PeptideAgent

Peptide blends

Blends such as GLOW, KLOW, and the Wolverine stack put two or more peptides in one vial under a catchy name. None of the 6 blends below has been tested as a combination in a published study, so each page grades every ingredient on its own and shows the legal status the mix inherits from its strictest ingredient.

By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed.  Last verified

All blends

Peptide blends with their ingredients, legal status, and WADA status
BlendIngredientsLegal statusWADA
CJC-1295 and ipamorelinCJC-1295 and IpamorelinRegulatory: No federal basis to compoundWADA: WADA prohibited
GLOWGHK-Cu, BPC-157, and TB-500Regulatory: No federal basis to compoundWADA: WADA prohibited
KLOWGHK-Cu, BPC-157, TB-500, and KPVRegulatory: No federal basis to compoundWADA: WADA prohibited
Sermorelin and ipamorelinSermorelin and IpamorelinRegulatory: No federal basis to compoundWADA: WADA prohibited
Tesamorelin and ipamorelinTesamorelin and IpamorelinRegulatory: No federal basis to compoundWADA: WADA prohibited
Wolverine stackBPC-157 and TB-500Regulatory: No federal basis to compoundWADA: WADA prohibited

What is in each blend?

CJC-1295 and ipamorelin

CJC-1295 and ipamorelin is a popular pairing of a long-acting GHRH analog with a selective ghrelin receptor agonist, sold premixed or as two vials to raise growth hormone. No study has tested the combination: CJC-1295 has small hormone trials, and ipamorelin has one small growth hormone pharmacology study in healthy men, while its only randomized trial was negative for a surgical use. Neither peptide can be lawfully compounded in the United States.

GLOW

GLOW is a nickname for a premixed injectable of three peptides: GHK-Cu, BPC-157, and TB-500. No published study has tested the combination in people or animals, so each ingredient is graded on its own below. Injectable GHK-Cu has no federal basis to be compounded, and HHS's October 28, 2026 draft policy covers BPC-157 and TB-500 only as single-ingredient products, so the blend has no lawful path.

KLOW

KLOW is a nickname for a premixed injectable of four peptides: the three in GLOW (GHK-Cu, BPC-157, and TB-500) plus KPV, an anti-inflammatory fragment of alpha-MSH. No study has tested the combination, and KPV itself has no human trial. The blend has no federal basis to be compounded: injectable GHK-Cu has none, and HHS's October 28, 2026 draft policy covers BPC-157, TB-500, and KPV only as single-ingredient products.

Sermorelin and ipamorelin

Sermorelin and ipamorelin is a pairing of GHRH(1-29), once sold as the approved drug Geref, with the ghrelin receptor agonist ipamorelin, marketed to raise growth hormone. No study has tested the combination. Sermorelin's compounding status is unsettled and ipamorelin has no federal basis to be compounded, so neither does the blend.

Tesamorelin and ipamorelin

The tesamorelin and ipamorelin blend pairs an FDA approved GHRH analog (Egrifta) with an unapproved ghrelin receptor agonist to raise growth hormone. No study has tested the combination. Tesamorelin alone has a lawful prescription path as Egrifta WR; the blend does not, because neither ingredient can be lawfully compounded.

Wolverine stack

The Wolverine stack is a nickname for BPC-157 and TB-500 used together, sold premixed or as two vials, for injury recovery. No study has tested the pair. BPC-157 rests mainly on animal data, and TB-500 has no human study: the trials often cited for it used full-length thymosin beta-4, a different substance. HHS's October 28, 2026 draft enforcement policy covers BPC-157 and TB-500 only as separate single-ingredient compounded products, so a mix of the two is not covered and has no lawful path.

For how the most searched blends differ, read KLOW vs GLOW; for why no stack has trial evidence, read peptide stacks ranked by the evidence for each part.

How to read a blend page

A blend is only as well studied as its least studied ingredient, and usually less: mixing peptides raises questions about stability, interactions, and combined side effects that no single-peptide study answers. It is also only as lawful as its least lawful ingredient. A licensed pharmacy may compound a mix only if every component is eligible under 503A, so one ineligible peptide leaves the whole vial with no federal basis to compound.

Blend pages never give doses, ratios, or instructions, and never name sellers. For each ingredient's full evidence, see the peptide index; for head-to-head evidence, see the comparisons; for the rules where you live, see peptide laws by state.